Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCAR1901 in Refractory Autoimmune Diseases
NCT07121777Phase 1Recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Aug 2025
- Primary completion
- Aug 2029
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LCAR1901 in rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), Sjögren's syndrome and 1 more, sponsored by The First Affiliated Hospital of USTC. Primary endpoint: Adverse events at 1 year. Started Aug 2025; status: recruiting.
02
Drugs
LCAR1901
03
Conditions
rheumatoid arthritis (RA)systemic lupus erythematosus (SLE)Sjögren's syndromesystemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT07121777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07121777.